Novozymes buys US probiotics company Microbiome Labs

Novozymes said the deal gives it broader access to the DKK40bn global market for human probiotics supplements and a well-established entry point into the important North American market, which is valued at DKK15bn and expected to grow with a high-single-digit rate over the next three to five years.

Chief executive officer Ester Baiget said: "Within a few years, Microbiome Labs has built a solid market position and become a key opinion leader on the microbiome in the consumer health industry, and I am very happy to welcome Microbiome Labs to the Novozymes family.

"With its solid product portfolio and position with health practitioners, the company is a natural fit and matches our strategy of winning through scientifically proven solutions with specific health benefits."